Abstract 134P
Background
NSCLC accounts for most lung cancers and has a poor 5-year survival. With an increasing number of systemic and targeted therapies, including immune checkpoint inhibitors (ICIs), it is becoming more important to develop predictive biomarkers to identify patient response to ICIs. Additionally, targeting cancer and stromal cell metabolism could be the key to overcoming immune checkpoint blockade (ICB) resistance.
Methods
Retrospective cohort of 28 nivolumab-treated NSCLC tissue cores (n = 28; 10/18 responders/non-responders) was profiled using a custom 44-plex immunofluorescence panel (incl. functional/metabolic markers) with the Phenocycler Fusion platform (Akoya Biosciences). We applied an unbiased spatial analytics and explainable AI pipeline, SpaceIQ, to capture emergent metabolic programs in spatial arrangements of unbiased cell types (microdomains, μD1 and μD2) predictive of ICI response. Predictive spatial networks implicated in known metabolic pathways are currently being verified by spatial transcriptomics.
Results
Non-responders had higher proportions of CD4 T cells with upregulated TCA cycle/downregulated glycolysis and pentose phosphate pathway (PPP). μD1 and μD2 were spatially anchored around tumor cells with upregulated TCA cycle and oxidative phosphorylation (OXPHOS) with additional NK cells and dendritic cells along with upregulated PPP in μD2. Each microdomain had distinct metabolic programs relating to catabolic (energy utilization) and anabolic (cellular biogenesis) pathways. μD1/μD2 were prognostic for overall survival (mean AUC = 0.86/0.82, +/-0.11), with median sensitivity (80%/80%) and specificity (66%/88%) for nivolumab-treated response.
Conclusions
The SpaceIQ platform infers distinct metabolic programs revealing spatially mediated roles for anabolic/catabolic pathways to predict immunotherapy response in NSCLC. Unbiased discrete cell typing allowed for functional characterization of tumor/stromal cells. Distinct spatial organization of metabolic activity encompassing glycolysis, TCA cycle, PPP, and OXPHOS may play a significant role in affecting clinical outcomes induced by ICI therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
PredxBio, Inc.
Funding
PredxBio, Inc.
Disclosure
R. Yan, S. Quinn, B. Falkenstein, S.C. Chennubhotla, F. Pullara: Financial Interests, Personal, Full or part-time Employment: PredxBio. All other authors have declared no conflicts of interest.
Resources from the same session
183P - Development of a cadherin-17 (CDH17) immunohistochemistry assay for use as a companion diagnostic for cabotamig in gastrointestinal cancers
Presenter: Dennis Wong
Session: Poster session 08
184P - From breast and gastric to beyond: Expanding HER2 detection in solid tumors using quantitative RNA and protein analysis
Presenter: Kristian Egebjerg
Session: Poster session 08
185P - Multi-omics profiling and clinical characterization of colon-like cancer of unknown primary (CUP)
Presenter: Maria Pouyiourou
Session: Poster session 08
186P - Differences in antigen and immune marker expression in lymphoepithelioma-like carcinoma (LELC) and nasopharyngeal carcinoma (NPC): A multiplex immunohistochemistry (mIHC), spatial transcriptomic and multiplex immunofluorescence (mIF)-based analysis
Presenter: Daniel Peh
Session: Poster session 08
187P - Organoid growth-based oncological sensitivity test (OncoSensi) for predicting radiation therapy outcomes in pharyngeal and esophageal cancer
Presenter: Dong Woo Lee
Session: Poster session 08
188P - Integration of immunohistochemistry and transcriptomics reveals new insights into the immune landscape of soft-tissue sarcomas
Presenter: Giulia Petroni
Session: Poster session 08
189P - An image-based deep learning prediction model for characterization of the drug tolerant persister cell state
Presenter: Lauren Cech
Session: Poster session 08
190P - A large scale proteogenomics atlas for precision oncology research
Presenter: Timothy Anthony Yap
Session: Poster session 08
191P - Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven tumors
Presenter: Francesco Facchinetti
Session: Poster session 08
192P - Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers
Presenter: Daniel Palmer
Session: Poster session 08